Rakesh Jain - Tekla Life Insider

Tekla Life Sciences Investors -- USA Fund  

USD 20.14  0.000001  0.00%

Independent Trustee

Dr. Rakesh K. Jain, Ph.D. is Independent Trustee of HQ Life Sciences Investors. Dr. Jain is the Andrew Werk Cook Professor of Tumor Biology in the Department of Radiation Oncology at Harvard Medical School and the Director of the Edwin L. Steele Laboratory of Tumor Biology at Massachusetts General Hospital, providing each Fund with a valuable perspective on emerging life sciences technologies. Dr. Jain cofounded XTuit Pharmaceuticals, Inc. in 2011, where he also serves as a board member. He serves on the Governance and Nominating Committee of each Fund. Prior to joining Harvard, he was professor of chemical engineering at Columbia University and Carnegie Mellon University. Dr. Jain is regarded as a pioneer in the fields of tumor biology, drug delivery, in vivo imaging and bioengineering. Dr. Jain has authored more than 600 publications. He serves on advisory panels to government, industry and academia, and has served or continues to serve on editorial advisory boards of twenty journals, including Journal of Clinical Oncology and Nature Reviews Clinical Oncology. He has received more than 70 major awards and lectureships, including a Guggenheim Fellowship, the Humboldt Senior Scientist Award, the National Cancer Institute Research Career Development Award and Outstanding Investigator Grant, the Academic Scientist of the Year Award from the Pharmaceutical Achievements Awards, the Distinguished Service Award from Nature Biotechnology and the Innovator Award from the DoD Breast Cancer Program. He is a member of all three branches of US National Academies the Institute of Medicine, the National Academy of Engineering and the National Academy of Sciences and is a member of the American Academy of Arts and Sciences.
Age: 66  Executive Since 2007      

Management Performance (%)

Similar Money Managers

Showing few of many executives

One Year Return

Alfred MurataPIMCO Income R
Joshua BarrickmanVanguard Total Bond Market II I
Amy GutmannVanguard Total Bond Market Idx
Joseph LoughreyVanguard Total Bond Market Idx
Carl KawajaAmerican Funds Europacific Grow
Alfred MurataPIMCO Income C
Kathryn HyattVanguard Total Bond Market Idx
JoAnn HeisenVanguard Total Bond Market Idx
Dina PerryAmerican Funds Income Fund of A
Peter VolanakisVanguard Total Bond Market Idx
Joshua BarrickmanVanguard Total Bond Market Idx
Emerson FullwoodVanguard Total Bond Market Idx
Andre PeroldVanguard Total Bond Market Idx
Rajiv GuptaVanguard Total Bond Market Idx
Heidi StamVanguard Total Bond Market Idx
Alfred RankinVanguard Total Bond Market Idx

Fund Summary

The fund is listed under null category and is part of null family.

Fix Portfolio

Optimize Your Risk-Return Tradeoff
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add Tekla Life Sciences Investors to your portfolio

Top Management

Tekla Life Sciences Leadership Team
William Reardon, Executive, CPA
Michael Bonney, Executive
Oleg Pohotsky, Executive, MBA
Lucinda Stebbins, Executive, CPA
Daniel Omstead, President
Uwe Reinhardt, Executive, Ph.D
Rakesh Jain, Executive

Fund Performance

Tekla Life Performance Indicators